Daconib 45 Tablets — Dacomitinib 45 mg (30 Tabs) Everest

Prescribed by oncologists for the first-line treatment of adult patients with:

• 🔹 Non-Small Cell Lung Cancer (NSCLC): Metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an approved test.

Sales Unit: Bottle containing 30 film-coated tablets (45 mg strength).

⚠️ APPLICATION INSTRUCTIONS:

• Standard Dosage: 45 mg (one tablet) taken orally once daily.
• Administration: Swallow tablets whole with water at approximately the same time each day. Can be taken with or without food. Do not chew, crush, or split.
• Duration: Treatment typically continues until disease progression or unacceptable toxicity occurs.
• ✋ Missed Dose: Take as soon as remembered. If less than 12 hours remain before the next scheduled dose, skip the missed dose. Do not take a double dose to make up for a missed one.

• ⛔ Pregnancy & Breastfeeding: Strictly contraindicated. Can cause fetal harm. Effective contraception is mandatory during treatment.
• Pediatric patients (safety and efficacy not established).
• Hypersensitivity to Dacomitinib.
• Severe hepatic or renal impairment requires caution and monitoring.

Side effects are common but manageable. Monitoring is essential:

• ⚠️ Skin Reactions: Rash, dry skin, paronychia (nail infection), and pruritus are very common.
• 🤢 Gastrointestinal: Diarrhea (frequent), stomatitis (mouth sores), decreased appetite, nausea.
• 🫁 Respiratory: Interstitial Lung Disease (ILD) is a rare but serious risk. Report new or worsening cough/shortness of breath immediately.
• 👀 Ocular: Conjunctivitis, dry eyes.